TrialBlood advances2026

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

Sonja Zweegman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.